use the following content for the summary:

REP17
:chart_with_upwards_trend: Sales Increase: $11,742.29
Top Products:
Januvia led the charge, contributing the bulk of the sales increase.
Followed by Lipitor and Keytruda, both of which also saw meaningful bumps.
Payer Impact:
Medicare was the primary driver, with over $9,800 in February sales, up from $3,900 in January.
Medicaid and Private also showed gains, but Medicare led by a wide margin.
Dimensional Impact:
Quantity increased from 166 units to 445 units — a +168% jump, indicating more frequent or higher-volume prescriptions.
Narrative: REP17 likely targeted high-potential Medicare prescribers and focused on promoted drugs like Januvia. The surge in units and alignment with a high-reimbursement payer (Medicare) made REP17 the top contributor.
:second_place_medal:
REP14
:chart_with_upwards_trend: Sales Increase: $8,639.82
Top Products: Strong performance from both Lipitor and Keytruda, signaling a cross-specialty strategy (Cardiology + Oncology).
Payer Impact: Similar to REP17, Medicare was the key driver of February sales. Medicaid also contributed meaningfully.
Dimensional Impact: Sharp increase in volume, suggesting REP14 expanded reach within their territory — possibly onboarding new prescribers or increasing frequency of engagement.
Narrative: REP14 appears to have balanced high-value product pushes with payer-friendly targeting, boosting both volume and margin.
:third_place_medal:
REP3
:chart_with_upwards_trend: Sales Increase: $7,333.42
Top Products: Primarily Keytruda, indicating a specialty/oncology focus.
Payer Impact: Almost entirely Medicare-driven — suggesting REP3 works with older patient demographics or oncologists.
Dimensional Impact: A jump from 0 to significant volume in February, pointing to either a new account onboarding or focused sampling and conversion strategy.
Narrative: REP3 likely broke into a key account in February, unlocking a high-potential Medicare prescriber and maximizing with a high-ticket product.
:1234:
REP6
:chart_with_upwards_trend: Sales Increase: $6,859.65
Top Products: Balanced growth across Januvia and Lipitor, two primary care staples.
Payer Impact: Broad contributions from both Medicare and Medicaid, which may indicate a territory with mixed socioeconomic demographics.
Dimensional Impact: Strong increase in volume with more moderate ticket size growth — pointing to more prescribers writing smaller but frequent scripts.
Narrative: REP6’s diversified base and consistent activity paid off in February, particularly in cost-sensitive payer environments.
:hand:
REP2
:chart_with_upwards_trend: Sales Increase: $4,428.06
Top Products: Primarily Lipitor, supported by Advil — pointing to a generalist or primary care route.
Payer Impact: Medicaid was the standout — an unusual case where lower-margin volume added up.
Dimensional Impact: Big jump from 0 to meaningful quantity, suggesting a new HCP relationship was activated.
Narrative: REP2 appears to have onboarded a new, Medicaid-heavy prescriber in February, driving quick wins through volume rather than margin.
:pushpin: Key Takeaways:
Medicare was the biggest payer contributor across all top reps.
Januvia and Lipitor were the most consistently contributing products.
The biggest gains were made either by:
Expanding volume within existing accounts, or
Onboarding new prescribers and unlocking dormant HCPs.